Dr. Ravandi on Vadastuximab Talirine Plus Hypomethylating Agents in AML
Farhad Ravandi-Kashani, MD, professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses vadastuximab talirine plus hypomethylating agents in acute myeloid leukemia.
Farhad Ravandi-Kashani, MD, professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses vadastuximab talirine plus hypomethylating agents (HMA) in acute myeloid leukemia (AML).
The CD33-directed antibody-drug conjugate vadastuximab talirine showed good tolerability in a phase I single-agent trial, says Ravandi, with the only toxicity being myelosuppression.
This led to a trial combining low doses of vadastuximab talirine with HMA, given on the last day of therapy with either azacitidine or decitabine.
Related Videos
Related Content
